The RXPC situation is NOT complex, IMO.
The takeover rumor is complex, yes, but it has to be to get around its logical fallacies and contradictions.
The RXPC situation is quite simple: the company got a device cleared by the FDA in 2006 but revenues never exceeded 5% of operating costs. As a result, The company defaulted on every loan they took out, the were delisted in 2011 when the SEC forced them to admit they had no shareholder equity, and today they don't have a facility or employees. Today, there are only two officers left, and one of them, the CEO, has been working on other ventures for the past two years.
The company currently has two "assets" -- a patent for DR-70 that expires in six weeks and a patent for CIT, an untested therapy that the company said in their last 10-K is worthless.
There is only one patent pending application for DR-70, and that application was rejected, then resubmitted as an RCE, and now sits in the RCE backlog at the USPTO where it probably won't even be opened again until 2016.
So it's very simple. This company is not a takeover candidate because there are no assets to take over. This company sits idle, no PR's, no SEC filings, no activity. How could it be simpler?
